SAB Biotherapeutics dosed first participants in Phase 1 trial of SAB-142 for Type 1 Diabetes

SAB Biotherapeutics, Inc.

First-in-human Phase 1 trial dosed in Australia; double-blind, placebo-controlled, single-ascending dose design.
SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin targeting immune cells that destroy pancreatic beta cells.
Phase 1 assesses safety, tolerability, PK/PD, and aims to establish proof of biological activity in T1D.
Company plans to file IND with FDA and CTA in UK/EU in 2024 to advance to Phase 2b study.
Trial led by Dr. Kristi McLendon at Nucleus Network; SAB-142 has potential as disease-modifying treatment for T1D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.